within Pharmacolibrary.Drugs.ATC.G;

model G03GA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 0.005,
    adminDuration  = 600,
    adminMass      = 0.012,
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Follitropin delta is a recombinant human follicle-stimulating hormone (r-hFSH) used for controlled ovarian stimulation in women undergoing assisted reproductive technologies such as in vitro fertilization. It is approved for clinical use as an infertility treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy premenopausal women receiving follitropin delta by subcutaneous administration.</p><h4>References</h4><ol><li><p>Shao, F, et al., &amp; Jonker, DM (2023). Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women. <i>Clinical drug investigation</i> 43(1) 37–44. DOI:<a href=&quot;https://doi.org/10.1007/s40261-022-01232-9&quot;>10.1007/s40261-022-01232-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36478528/&quot;>https://pubmed.ncbi.nlm.nih.gov/36478528</a></p></li><li><p>Abe, Y, &amp; Ozeki, Y (2022). [Pharmacological profile, clinical efficacy, and safety of Follitropin Delta produced by recombinant DNA technology in a human cell line (REKOVELLE. <i>Nihon yakurigaku zasshi. Folia pharmacologica Japonica</i> 157(1) 76–84. DOI:<a href=&quot;https://doi.org/10.1254/fpj.21079&quot;>10.1254/fpj.21079</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34980816/&quot;>https://pubmed.ncbi.nlm.nih.gov/34980816</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03GA10;
